Flash Finance

Thyrocare Technologies LimitedTHYROCARECorporate

Healthcare Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹485.25
MCap ₹7,723 Cr · P/E 47.4
Thyrocare Technologies Limited — Stock analysis & AI research Thyrocare Technologies Limited — Seasonality — best & worst months Thyrocare Technologies Limited — Technical indicators & charts Thyrocare Technologies Limited — Technical setup — score, trend, support & resistance Thyrocare Technologies Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 📈 RSI Oversold Stocks📈 Lowest Technical Score 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹226 Cr
Sales · Jun 2026
+26.1% YoY
₹76 Cr
Operating Profit · Jun 2026
+33.8% YoY
33.5%
OPM % · Jun 2026
+6.0% YoY
₹50 Cr
Net Profit · Jun 2026
+39.2% YoY
₹3.15
EPS · Jun 2026
-53.7% YoY

📝 Thyrocare Technologies Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Thyrocare Technologies Limited reported revenue of ₹226 crore for the quarter ended June 2026 (Q1 FY27), up 26.1% from ₹179 crore in the same quarter last year, and up 7.1% sequentially over the March 2026 quarter.

Net profit rose 39.2% year-on-year to ₹50 crore, from ₹36 crore. Earnings per share (EPS) came in at ₹3.15.

Operating profit stood at ₹76 crore — an operating margin (OPM) of 33.5%, compared with 31.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Thyrocare Technologies Limited posted revenue of ₹774 crore, a growth of 22.2% over FY25, with a net profit of ₹149 crore (up 55.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹821 crore with a net profit of ₹163 crore.

Valuation snapshot

At the current price of ₹485.25, THYROCARE has a market capitalisation of ₹7,723 crore and a trailing P/E of about 47.4.

Within the Healthcare industry, it is the 6th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.02%, foreign institutional investors (FIIs) 9.37%, domestic institutional investors (DIIs) 25.92%, public shareholders 13.70% of Thyrocare Technologies Limited.

Promoter holding slipped from 60.92% to 51.02% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹7,723 Cr
Current Price ?
₹485.2
P/E ?
47.40above ind
Industry P/E ?
34.70
P/B ?
13.77
P/S ?
9.41
P/FCF ?
40.44
Enterprise Value ?
₹7,771 Cr
EV/EBITDA ?
28.22
PEG ?
1.22
Earnings Yield ?
2.9%
Dividend Yield ?
1.93%
Profitability & Returns
Sales (TTM) ?
₹821 Cr
OPM ?
33.5%
Profit after tax (TTM) ?
₹163 Cr
EPS (TTM) ?
₹10.24
ROCE ?
36.0%
ROE ?
29.0%
ROA ?
22.9%
Growth
Sales — latest qtr ?
₹226 Cr
PAT — latest qtr ?
₹50 Cr
YoY qtr sales growth ?
26.1%
YoY qtr profit growth ?
39.2%
Sales growth (3y) ?
17%
Sales growth (5y) ?
10%
Profit growth (3y) ?
39%
Profit growth (5y) ?
5%
Financial Health
Debt ?
₹48 Cr
Debt to Equity ?
0.09
Interest Coverage ?
94.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.02%
Change in promoter holding ?
-20.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.8%
Return 6 months ?
24.7%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 125124136123141144163153174179202182211226 +26.1% +7.1%
Operating Profit 2333373134424940565769587376 +33.8% +4.1%
Other Income 20223324542344 -11.4% -5.6%
Interest 11111110111-011 +103.2% -11.9%
Depreciation 99911109101512910201311 +25.5% -13.2%
Profit Before Tax 1524282125354028485161376267 +30.9% +7.5%
Net Profit 1017201519253019223643264450 +39.2% +15.1%
EPS 1.881.053.830.943.634.755.591.204.086.808.121.642.753.15 -53.7% +14.5%
OPM % 18.2% 26.6% 26.9% 25.2% 23.8% 29.5% 29.9% 26.1% 32.0% 31.6% 34.1% 31.9% 34.5% 33.5% +6.0% -2.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹634 Cr ₹774 Cr ₹821 Cr +22.2%
Operating Profit ₹187 Cr ₹256 Cr ₹275 Cr +37.2%
OPM % 29.48% 33.11% 33.55% +12.3%
NPM % 15.10% 19.22% 19.84% +27.3%
Other Income ₹14 Cr ₹13 Cr ₹13 Cr -3.2%
Depreciation ₹46 Cr ₹51 Cr ₹53 Cr +10.8%
Interest ₹2 Cr ₹2 Cr ₹3 Cr +0.9%
EBIT ₹141 Cr ₹205 Cr ₹222 Cr +45.9%
PBT ₹151 Cr ₹210 Cr ₹226 Cr +39.1%
Tax ₹-25 Cr ₹-32 Cr ₹-30 Cr -27.0%
Net Profit ₹96 Cr ₹149 Cr ₹163 Cr +55.5%
EPS ₹15.62 ₹19.31 ₹15.66 +23.6%
Material Cost ₹137 Cr ₹209 Cr ₹216 Cr +52.9%
Employee Cost ₹86 Cr ₹128 Cr ₹135 Cr +49.9%
Extraordinary Items — ₹-6 Cr ₹-6 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 535353159 +200.0%
Reserves 468461484402 -16.9%
Borrowings 21392348 +108.7%
Other Liabilities 7068116102 -12.1%
Total Liabilities 612620676711 +5.2%
Fixed Assets 157159158180 +13.9%
CWIP 11143 -78.6%
Investments 274291284294 +3.5%
Other Assets 180169221234 +5.9%
Total Assets 612620676711 +5.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 120155179206 +15.1%
Cash from Investing Activity -32-80-43-21 +51.2%
Cash from Financing Activity -88-84-124-167 -34.7%
Net Cash Flow 1-91218 +50.0%
Free Cash Flow 99114144191 +32.6%
CFO/OP 129%135%121%104% -14.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 63284033 -17.5%
Inventory Days 631069381 -12.9%
Days Payable 528314196 -31.9%
Cash Conversion Cycle 7451-918 +300.0%
Working Capital Days 34141824 +33.3%
ROCE % 15%18%26%36% +38.5%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 71.06%71.06%60.93%60.92%51.02% -16.3%
FIIs 3.23%4.85%4.96%5.37%9.37% +74.5%
DIIs 14.54%13.47%20.52%21.00%25.92% +23.4%
Public 11.18%10.61%13.61%12.71%13.70% +7.8%
No. of Shareholders 54,56654,14277,61973,37775,186 +2.5%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Thyrocare Technologies Limited's revenue in Q1 FY27?
Thyrocare Technologies Limited reported revenue of ₹226 crore for the quarter ended June 2026 (Q1 FY27), up 26.1% from ₹179 crore in the same quarter last year, and up 7.1% sequentially over the March 2026 quarter.
What was Thyrocare Technologies Limited's net profit in Q1 FY27?
Net profit rose 39.2% year-on-year to ₹50 crore, from ₹36 crore. Earnings per share (EPS) came in at ₹3.15.
What is THYROCARE's market capitalisation and P/E ratio?
At the current price of ₹485.25, THYROCARE has a market capitalisation of ₹7,723 crore and a trailing P/E of about 47.4.
Who owns Thyrocare Technologies Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.02%, foreign institutional investors (FIIs) 9.37%, domestic institutional investors (DIIs) 25.92%, public shareholders 13.70% of Thyrocare Technologies Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI